Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome, Including Long-term Safety Follow-up

NCT05457010 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT05457010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05457010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome, Including Long-term Safety Follow-up
Lead sponsor
Kite, A Gilead Company
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 28, 2022
Completion date
October 31, 2026
Enrollment
24 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndromes